Hepatocellular carcinoma

The Lancet

Volumn 380, Issue 9840, 2012, Pages 470-

  Oliveri, Roberto S ^a,b   Wetterslev, Jørn ^a   Gluud, Christian ^a  

^a Centre for Clinical Intervention Research   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER PATIENT; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL (TOPIC); HUMAN; LETTER; LIVER CELL CARCINOMA; META ANALYSIS (TOPIC); METHODOLOGY; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC);

EID: 84864759139     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61285-9     Document Type: Letter

References (5)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
2. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; 3: CD004787.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
4. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-39.
5. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.